Cochrane · systematic review · CD007479
Pericyazine for schizophrenia
Matar, HE, Almerie, MQ, Makhoul, S, et al. · Cochrane Database of Systematic Reviews · 2014 · Cochrane Library
SchizophreniaAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
13
current version
GRADE rated
7
No studies
6
Included studies
NR
No studies 6 · 46.2%Ungraded 0 · 0%Very low 7 · 53.8%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Pericyazine versus Typical antipsychotic for schizophrenia
Population: patients with schizophrenia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Global state ‐ not improved Pericyazine vs Typical antipsychotic | RR 1.24 [0.93, 1.66] | 2 studies · 122 participants | Very low Downgraded: risk of bias, imprecision, publication bias |
Global state ‐ relapse Pericyazine vs Typical antipsychotic | no estimate extracted | 1 study · 80 participants | Very low Downgraded: risk of bias, imprecision, publication bias |
Adverse events ‐ for specific reasons ‐ Extrapyramidal side effect Pericyazine vs Typical antipsychotic | RR 0.59 [0.38, 0.89] | 3 studies · 163 participants | Very low Downgraded: risk of bias, imprecision, publication bias |
Mental state not reported Pericyazine vs Typical antipsychotic | no estimate extracted | NR | No studies |
Leaving the study early for specific reasons Pericyazine vs Typical antipsychotic | RR 0.46 [0.11, 1.9] | 2 studies · 71 participants | Very low Downgraded: risk of bias, imprecision, publication bias |
Behaviour not reported Pericyazine vs Typical antipsychotic | no estimate extracted | NR | No studies |
Economic outcomes not reported Pericyazine vs Typical antipsychotic | no estimate extracted | NR | No studies |
Pericyazine versus Atypical antipsychotic for schizophrenia
Population: patients with schizophrenia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Global state ‐ not improved Pericyazine vs Atypical antipsychotic | RR 0.97 [0.67, 1.42] | 1 study · 93 participants | Very low Downgraded: risk of bias, imprecision, publication bias |
Adverse Effects ‐ Extrapyramidal symptoms Pericyazine vs Atypical antipsychotic | RR 2.69 [1.35, 5.36] | 1 study · 93 participants | Very low Downgraded: risk of bias, imprecision, publication bias |
Mental state not reported Pericyazine vs Atypical antipsychotic | no estimate extracted | NR | No studies |
Leaving the study early for specific reasons Pericyazine vs Atypical antipsychotic | RR 0.46 [0.11, 1.9] | 1 study · 93 participants | Very low Downgraded: risk of bias, imprecision, publication bias |
Behaviour not reported Pericyazine vs Atypical antipsychotic | no estimate extracted | NR | No studies |
Economic outcomes not reported Pericyazine vs Atypical antipsychotic | no estimate extracted | NR | No studies |